Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells
Laura Damele, Adriana Amaro, Alberto Serio, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 319-319
Open Access | Times Cited: 13

Showing 13 citing articles:

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
Ran Jing, Irene Scarfo, Mohamad Najia, et al.
Cell stem cell (2022) Vol. 29, Iss. 8, pp. 1181-1196.e6
Open Access | Times Cited: 61
Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?
Laura Damele, Grazia Maria Spaggiari, Monica Parodi, et al.
Cancers (2022) Vol. 14, Iss. 18, pp. 4439-4439
Open Access | Times Cited: 15
Emerging role of EZH2 in rheumatic diseases: A comprehensive review
Wang‐Dong Xu, Qi Huang, An‐Fang Huang
International Journal of Rheumatic Diseases (2022) Vol. 25, Iss. 11, pp. 1230-1238
Closed Access | Times Cited: 9
ILC3: a case of conflicted identity
Ivan Koprivica, Suzana Stanisavljević, Dragica Mićanović, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients
Wei Peng, Wei Tang, Jian‐Di Li, et al.
PeerJ (2022) Vol. 10, pp. e13708-e13708
Open Access | Times Cited: 5
Role of EZH2 in bone marrow mesenchymal stem cells and immune–cancer interactions
Zhaoyun Liu, Yue Jia, Yixuan Guo, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 169, pp. 103547-103547
Closed Access | Times Cited: 6
Efficient In Vitro Generation of IL-22-Secreting ILC3 From CD34+ Hematopoietic Progenitors in a Human Mesenchymal Stem Cell Niche
Sabrina B. Bennstein, Sandra Weinhold, Özer Degistirici, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 6
Stem Cell Therapy and Innate Lymphoid Cells
Divya Verma, Mukesh Verma, Rangnath Mishra
Stem Cells International (2022) Vol. 2022, pp. 1-12
Open Access | Times Cited: 3
Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer
Jolien M.R. Van der Meer, Ingrid Bulder, Carlijn Kuijk, et al.
Cytotherapy (2023) Vol. 26, Iss. 2, pp. 136-144
Open Access | Times Cited: 1
Peer Review #3 of "Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients (v0.2)"
Wei Peng, Jian‐Di Li, Rong‐Quan He, et al.
(2022)
Open Access
Peer Review #3 of "Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients (v0.1)"
Wei Peng, Jian‐Di Li, Rong‐Quan He, et al.
(2022)
Open Access
Peer Review #1 of "Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients (v0.1)"
Wei Peng, Jian‐Di Li, Rong‐Quan He, et al.
(2022)
Open Access
Peer Review #4 of "Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients (v0.1)"
Wei Peng, Jian‐Di Li, Rong‐Quan He, et al.
(2022)
Closed Access
Page 1

Scroll to top